The clinical profile is the real differentiator. Boey targets SNAP-25 and has a short half-life in neuronal cells, which produces rapid onset and rapid offset. Two randomized, placebo-controlled Phase 3 trials (M21-500 and M21-508) enrolled 947 patients who received 700 U total dose or placebo. At Day 7, 60% of patients in M21-500 and 65.7% in M21-508 achieved a ≥2-grade improvement in frown line severity on the 4-point Frown Severity Scale, both investigator and subject assessed (p<0.0001 vs. placebo). At the 8-hour mark, 7.1% of patients in M21-500 showed that same improvement level, compared to placebo (p=0.0006). In M21-508, 5.3% of patients showed ≥2-grade improvement at 8 hours.
Patients returned to baseline severity in approximately 21 days after administration in the intent-to-treat population. In M21-500, 2.7% of patients who achieved ≥2-grade improvement at Day 7 had returned to baseline by Day 21 (p=0.0385 vs. placebo). In M21-508, 1.4% of patients showed that pattern.
The adverse event profile in the studies included eyelid ptosis (uncommon), brow ptosis (uncommon), and Mephisto sign (rare). The document does not specify the rate of these events or how they compare to existing neurotoxins.
Glabellar lines are the vertical lines between the eyebrows, commonly called frown lines. They form as people repeatedly contract facial muscles when they frown, concentrate, or squint. Boey is indicated for the temporary improvement of moderate to severe glabellar lines only.
Allergan's own survey data, cited in the press release, found that 80% of respondents are open to trying new options and 79% wish they could preview results before committing. Robert Schuller, General Manager of Allergan Aesthetics Canada, framed Boey as addressing "the hesitant and curious patient, allowing them to try on the look, before committing to longer-lasting results. Dr. Julia Carroll, a dermatologist at Compass Dermatology, noted that "patients vary in what they want from aesthetic options, and some want to see how a option may look and feel before they commit to a longer-lasting result."
The authorization marks Allergan Aesthetics' growth in its neurotoxin portfolio in Canada, where the company has a longstanding history with BOTOX COSMETIC. Allergan Aesthetics develops, manufactures, and markets leading aesthetics brands and products including facial injectables, body contouring, plastics, and skin care.
The document does not discuss pricing, how much Boey costs or when it will be available in Canada. It also does not address whether Boey has been submitted to the FDA or other regulators outside Canada, or whether it will be marketed under the same name internationally. The press release does not specify whether practitioners will need new training or certification to administer Boey, or how dosing compares to other neurotoxins on a unit-for-unit basis.
Business information, not medical or legal advice. Verify regulatory status at FDA.gov.
